Loading clinical trials...

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers. | Clinical Trials | Clareo Health

TERMINATEDPHASE1

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

NCT01847222•Prolong Pharmaceuticals

View on ClinicalTrials.gov

Summary

Safety assessment of SANGUINATE™ in Healthy Volunteers.

Detailed Description

Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE™ in Healthy Volunteers.

Eligibility

Age

18 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Male Volunteers;
•Age ≥18 years and ≤45 years;
•BMI ≥20- ≤30 kg/m²
•No clinically significant screening observations

Exclusion Criteria

•Female volunteers;
•Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, chronic hepatic disease or any other disease which in the judgment of the Investigator would interfere with the study or confound the results;
•History of allergy or major allergic reactions considered to be clinically significant by the Investigator;
•Any screening assessment determined to be clinically significant by the Investigator;
•Donate blood within 60 days of screening or otherwise experienced blood loss \>250 mL within the same period;

Locations (1)

Rambam Health Care Facility

Haifa, Israel

Key Dates

Start Date

May 1, 2013

Primary Completion Date

May 1, 2014

Completion Date

August 1, 2014

Last Updated

January 6, 2015

Enrollment

ACTUAL participants

Conditions

Drug Safety

Interventions

SANGUINATE™

BIOLOGICAL

Normal Saline Solution

DRUG

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

NCT01722916

Drug Safety

View study

NOT_YET_RECRUITINGPHASE1

Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.

NCT06889376

Drug Safety

View study

UNKNOWNPHASE1/PHASE2

Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis

NCT04785027

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

Inclusion Criteria

Exclusion Criteria

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.

Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

Remegal Different Doses in Patients With Refractory Partial Seizures